Ascletis Pharma is working on two drugs to treat hepatitis C. Photo: Shutterstock

Singapore sovereign wealth fund GIC to invest US$75 million in Chinese drug maker Ascletis’ Hong Kong IPO

Topic |   IPO

TOP PICKS

Ascletis Pharma is working on two drugs to treat hepatitis C. Photo: Shutterstock
READ FULL ARTICLE